Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - EyePoint Pharmaceuticals, Inc. | d389611dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2012
PSIVIDA CORP.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-51122 | 26-2774444 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
400 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices) (Zip Code)
(617) 926-5000
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On August 1, 2012, pSivida Corp. (“pSivida”) issued a press release announcing that its partner Alimera Sciences, Inc. intends to resubmit its application for ILUVIEN® for diabetic macular edema to the U.S. Food and Drug Administration using data from its two previously completed pivotal Phase III clinical trials (FAME™ Study). pSivida’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 10.1 | pSivida Corp. 2008 Incentive Plan (incorporated by reference to Exhibit 10.41 to the Current Report on Form 8-K filed by pSivida on June 19, 2008). | |
| 99.1 | Press Release of pSivida dated August 1, 2012. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 1, 2012
| PSIVIDA CORP. | ||||
| By: | /s/ Lori Freedman | |||
| Name: | Lori Freedman | |||
| Title: | Vice President Corporate Affairs, General Counsel and Secretary | |||
EXHIBIT INDEX
| Exhibit |
Description | |
| 10.1 | pSivida Corp. 2008 Incentive Plan (incorporated by reference to Exhibit 10.41 to the Current Report on Form 8-K filed by pSivida on June 19, 2008). | |
| 99.1 | Press Release of pSivida dated August 1, 2012. | |